An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study-Reference-Cited by-同舟云学术

An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study

Published:2023-01 Issue:1 Volume:14 Page:101396
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Hiroi Takayuki,Hosoi Hiroki,Kuriyama Kodai,Murata Shogo,Morimoto Masaya,Mushino Toshiki,Nishikawa Akinori,Tamura Shinobu,Sonoki Takashi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference42 articles.

1. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era;Zhou;Blood.,2014

2. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood.,2006

3. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010;Issa;Haematologica.,2015

4. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification;Muto;Cancer Med.,2018

5. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma;Carson;J. Geriatr. Oncol.,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-05-25

2. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma;Journal of Clinical and Experimental Hematopathology;2023-12-26

3. Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology/oncology departments based on the relative dose intensity of methotrexate;Oncology Letters;2023-09-19